Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AVIR
stocks logo

AVIR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.485
+21.25%
--
--
-0.530
+32.5%
--
--
-0.520
+18.18%
Estimates Revision
The market is revising No Change the revenue expectations for Atea Pharmaceuticals, Inc. (AVIR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -8.31%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-9.21%
In Past 3 Month
Stock Price
Go Down
down Image
-8.31%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Atea Pharmaceuticals Inc (AVIR.O) is -1.55, compared to its 5-year average forward P/E of -59.00. For a more detailed relative valuation and DCF analysis to assess Atea Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-59.00
Current PE
-1.55
Overvalued PE
251.23
Undervalued PE
-369.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
6.90
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
28.50
Undervalued EV/EBITDA
-14.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7.49
Current PS
0.00
Overvalued PS
22.07
Undervalued PS
-7.09
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

AVIR News & Events

Events Timeline

(ET)
2025-11-07
08:06:54
Atea Pharmaceuticals to Present Data on BEM and RZR
select
2025-10-07 (ET)
2025-10-07
08:19:06
Atea Pharmaceuticals to showcase findings on the combination of bemnifosbuvir and ruzasvir
select
2025-06-24 (ET)
2025-06-24
07:09:46
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
09-02Newsfilter
Atea Pharmaceuticals to Showcase at the 23rd Annual Global Healthcare Conference Hosted by Morgan Stanley

  • Atea Pharmaceuticals Conference Participation: Atea Pharmaceuticals will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, with a live webcast available on their website.

  • Company Focus and Development: Atea is a clinical-stage biopharmaceutical company specializing in oral antiviral therapies, currently focusing on the Phase 3 development of a combination treatment for HCV using bemnifosbuvir and ruzasvir.

[object Object]
Preview
9.5
08-08NASDAQ.COM
Atea (AVIR) Q2 Loss Narrows 8%

  • Financial Performance: Atea Pharmaceuticals reported a GAAP net loss per share of $0.44 for Q2 2025, which was better than expected and improved from the previous year, while maintaining a strong cash position of $379.7 million despite no revenue due to its pre-commercial status.

  • Clinical Development Focus: The company is advancing its Phase 3 clinical trials for hepatitis C treatments, emphasizing cost control and strategic planning amidst competition in the market, with no formal financial guidance provided for future quarters.

[object Object]
Preview
9.0
06-24NASDAQ.COM
Atea Pharmaceuticals Launches Phase 3 C-FORWARD Trial for HCV Treatment Regimen Combining Bemnifosbuvir and Ruzasvir

  • Phase 3 C-FORWARD Trial Announcement: Atea Pharmaceuticals has initiated the Phase 3 C-FORWARD trial to evaluate the efficacy of bemnifosbuvir and ruzasvir in treating hepatitis C virus (HCV), aiming for a shorter treatment duration and lower risk of drug-drug interactions compared to existing therapies.

  • Global Health Impact of HCV: HCV remains a significant global health issue, affecting approximately 50 million people worldwide, with 2.4 to 4 million chronic cases in the US, highlighting the need for effective and patient-friendly treatment options.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Atea Pharmaceuticals Inc (AVIR) stock price today?

The current price of AVIR is 3.09 USD — it has increased 0 % in the last trading day.

arrow icon

What is Atea Pharmaceuticals Inc (AVIR)'s business?

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.

arrow icon

What is the price predicton of AVIR Stock?

Wall Street analysts forecast AVIR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVIR is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Atea Pharmaceuticals Inc (AVIR)'s revenue for the last quarter?

Atea Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Atea Pharmaceuticals Inc (AVIR)'s earnings per share (EPS) for the last quarter?

Atea Pharmaceuticals Inc. EPS for the last quarter amounts to -0.53 USD, increased 43.24 % YoY.

arrow icon

What changes have occurred in the market's expectations for Atea Pharmaceuticals Inc (AVIR)'s fundamentals?

The market is revising No Change the revenue expectations for Atea Pharmaceuticals, Inc. (AVIR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -8.31%.
arrow icon

How many employees does Atea Pharmaceuticals Inc (AVIR). have?

Atea Pharmaceuticals Inc (AVIR) has 56 emplpoyees as of December 05 2025.

arrow icon

What is Atea Pharmaceuticals Inc (AVIR) market cap?

Today AVIR has the market capitalization of 241.41M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free